Background: Antiretroviral therapy (ART) and control of HIV replication does not fully restore perturbations within resting (CD19+CD27+CD21+) and activated (CD19+CD27+CD80+) memory B cell compartments. This study was based on the hypothesis that ongoing macrophage activation and HIVassociated inflammation contributes to B cell abnormalities. Methodology: Longitudinal cellular and soluble plasma markers for inflammation were evaluated in 43 healthy controls (HC) and 17 behaviorally-infected HIV-1+ subjects ages 18-25 years. Multicolor flow cytometry analysis of B cell subsets and assessment of markers of macrophage (sCD163 and sCD14) and lymphocyte (sCD27) were measured by ELISA. Assays were performed prior to and at 24 and 48 weeks following ART. All HIV-1 subjects suppressed HIV to < 50 copies/ml. Healthy controls and HIV+ treated subjects were also compared pair-wise and longitudinally at study entry (prior to ART), 24 weeks and 48 weeks on therapy by non-parametric rank sum. Results: Compared to HC, resting memory B cells were lower and activated B cells were higher among HIV+ subjects at all time points before and after ART {22.6 } 8.1% (HC) versus 16.4 } 6.7% (HIV+ at 48 weeks) for resting memory, p=0.0081, and 11.5 } 5.3% (HC) versus 15.2 } 5.1% (HIV+ at 48 weeks), for activated B cells, p=0.0415, Mann-Whitney}, Control of viral replication failed to decrease the proportions of activated B cells or increase memory B cells after 48 weeks on therapy. Compared to HC, sCD14, sCD27 and sCD163 all remained significantly elevated in HIV+ subjects at 48 weeks following therapy (p=0.0027, p<0.0001, and p=0.0142, respectively, Mann-Whitney). Regression analysis revealed a positive correlation between the decrease in resting memory B cells and levels of sCD14 at 48 weeks on therapy (r=0.51, p=0.038, Spearman test) but sCD163 and sCD27 did not correlate with the extent of B cell activation. Results also showed a positive correlation between the increase in activated B cells and the elevation of sCD14 24 weeks following therapy (r=0.54, p=0.028 Spearman). Conclusions: Elevated levels of sCD14, a biomarker of macrophage activation, is the result of LPS binding to TLR4. Our results show that chronic B cell activation also reflects ongoing inflammation due to microbial translocation that may contributes to ongoing B cell dysfunction, even in HIV-infected subjects who control viral replication with ART.